ea0029p814 | Endocrine tumours and neoplasia | ICEECE2012
Bernard V.
, Lombard-Bohas C.
, Goichot B.
, Rohmer V.
, Guimbaud R.
, Niccoli P.
, Chougnet C.
, Ruszniewski P.
, Baudin E.
Background: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and everolimus could be a new therapeutic option.Methods: We conducted a restrospective multicentric study within the French group of endocrine tumors to evaluate the time to first symptomatic recurrence (TSR) in patients with RHMI after everolimus initiation. Ongoing hyperglycemic medical options and safety were recorded.</...